Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
CRVS Stock Chart & Stats
$20.46
-$0.10(-1.74%)
At close: 4:00 PM EST
$20.46
-$0.10(-1.74%)
Day’s Range― - ―
52-Week Range$2.54 - $26.95
Previous CloseN/A
Volume202.27K
Average Volume (3M)5.56M
Market Cap
$1.71B
Enterprise Value$1.71B
Total Cash (Recent Filing)$65.69M
Total Debt (Recent Filing)$1.01M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Mar 05, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding83,767,650
10 Day Avg. Volume2,762,904
30 Day Avg. Volume5,564,527
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)10.02
Price to Sales (P/S)0.00
P/FCF Ratio-12.83
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-44.54
Forecast
1Y Price Target
$31.80Price Target Upside55.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 1 expansion cohort demonstrated a clear separation versus placebo in refractory atopic dermatitis, indicating potential meaningful benefit for patients who failed prior biologic and JAK inhibitor therapies.
Development And Commercial OutlookFinalized Phase 2 design and planned initiation in early 2026, together with multiple major clinical readouts slated for 2026, supports upside to market penetration and valuation if trials meet endpoints.
Safety And TolerabilitySoquelitinib showed a safety profile comparable to placebo in treated patients, reducing concerns about adverse events that could hinder regulatory review or adoption.
Bears Say
Commercial And Partnership ExecutionCommercial, partnership, and execution challenges could limit market access and slow adoption, putting downward pressure on the stock if planned collaborations do not materialize.
Financial PositionNo reported product revenues leaves the company reliant on external financing and partnership deals to fund development, increasing dilution and execution risk for investors.
Intellectual Property RiskIntellectual property disputes or weak patent coverage could erode competitive barriers and reduce long-term revenue potential even in the event of favorable clinical outcomes.
Corvus Pharmaceuticals News
CRVS FAQ
What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?
Corvus Pharmaceuticals Inc lowest stock price was $2.54 and its highest was $26.95 in the past 12 months.
What is Corvus Pharmaceuticals Inc’s market cap?
Corvus Pharmaceuticals Inc’s market cap is $1.71B.
When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?
Corvus Pharmaceuticals Inc’s upcoming earnings report date is Mar 05, 2026 which is in 23 days.
How were Corvus Pharmaceuticals Inc’s earnings last quarter?
Corvus Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.127 by $0.007.
Is Corvus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc pay dividends?
Corvus Pharmaceuticals Inc does not currently pay dividends.
What is Corvus Pharmaceuticals Inc’s EPS estimate?
Corvus Pharmaceuticals Inc’s EPS estimate is -0.13.
How many shares outstanding does Corvus Pharmaceuticals Inc have?
Corvus Pharmaceuticals Inc has 83,767,650 shares outstanding.
What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.127. Following the earnings report the stock price went down -1.44%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in CRVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corvus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.80 (55.43% Upside)
$31.80 (55.43% Upside)
Blogger Sentiment
Bullish
CRVS Sentiment 75%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 18.6%
Last 30 Days ▲ 18.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
279.59%
12-Months-Change
Fundamentals
Return on Equity
-35.82%
Trailing 12-Months
Asset Growth
36.83%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
CRVS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented significant positive developments, including a notable reduction in net loss, a strong cash position, and successful clinical trial progress for soquelitinib. However, increased R&D expenses and delays in trial result reporting were challenges. Overall, the positive aspects, particularly related to clinical advancements and financial improvements, seem to outweigh the negatives.View all CRVS earnings summariesCRVS Stock 12 Month Forecast
Average Price Target
$31.80
▲(55.43% Upside)
Technical Analysis
Ownership Overview
22.92% Insiders
6.53% Mutual Funds
0.04% Other Institutional Investors
59.21% Public Companies and
Individual Investors